Search This Blog

Thursday, July 23, 2020

Lannett launches generic version of BI heart drug

Lannett Company (NYSE:LCI) announces the commercial launch of Mexiletine Hydrochloride Capsules 150 mg, 200 mg and 250 mg, a generic equivalent to Boehringer Ingelheim’s antiarrhythmic drug Mexitil (mexiletine hydrochloride, USP).
Per IQVIA, the U.S. market is ~$16M.

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)